Returns On Capital Signal Tricky Times Ahead For National Research (NASDAQ:NRC)

What are the early trends we should look for to identify a stock that could multiply in value over the long term? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. So when we looked at National Research (NASDAQ:NRC), they do have a high ROCE, but we weren't exactly elated from how returns are trending.

Advertisement

Understanding Return On Capital Employed (ROCE)

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for National Research, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.26 = US$28m ÷ (US$141m - US$36m) (Based on the trailing twelve months to June 2025).

Therefore, National Research has an ROCE of 26%. That's a fantastic return and not only that, it outpaces the average of 11% earned by companies in a similar industry.

View our latest analysis for National Research

roce
NasdaqGS:NRC Return on Capital Employed September 26th 2025

While the past is not representative of the future, it can be helpful to know how a company has performed historically, which is why we have this chart above. If you'd like to look at how National Research has performed in the past in other metrics, you can view this free graph of National Research's past earnings, revenue and cash flow.

What Can We Tell From National Research's ROCE Trend?

On the surface, the trend of ROCE at National Research doesn't inspire confidence. To be more specific, while the ROCE is still high, it's fallen from 50% where it was five years ago. On the other hand, the company has been employing more capital without a corresponding improvement in sales in the last year, which could suggest these investments are longer term plays. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line.

Our Take On National Research's ROCE

In summary, National Research is reinvesting funds back into the business for growth but unfortunately it looks like sales haven't increased much just yet. Since the stock has declined 70% over the last five years, investors may not be too optimistic on this trend improving either. On the whole, we aren't too inspired by the underlying trends and we think there may be better chances of finding a multi-bagger elsewhere.

One final note, you should learn about the 4 warning signs we've spotted with National Research (including 1 which is potentially serious) .

National Research is not the only stock earning high returns. If you'd like to see more, check out our free list of companies earning high returns on equity with solid fundamentals.

Valuation is complex, but we're here to simplify it.

Discover if NRC Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:NRC

NRC Health

Provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States.

Moderate risk with imperfect balance sheet.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5362.1% undervalued
135 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18053.7% undervalued
17 users have followed this narrative
1 users have commented on this narrative
10 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.324.1% undervalued
8 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2450.4% undervalued
30 users have followed this narrative
2 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

KA
kapirey
UNCY logo
kapirey on Unicycive Therapeutics ·

Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization

Fair Value:US$9.1710.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
1364 logo
kapirey on Guming Holdings ·

A scaled, high-growth, franchise-driven beverage leader with strong penetration in China

Fair Value:HK$47.5650.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
HedgeY
IONQ logo
HedgeY on IonQ ·

The Best-Funded Quantum Platform and Still a Stock Priced for Perfection

Fair Value:US$4816.4% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8590.1% undervalued
108 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.227.7% undervalued
70 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74018.5% undervalued
35 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative